Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | PPOX | P50336 | 1/20 | 0.56 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.53 |
| ▸ | DTYMK | P23919 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889423 | 0.88 | MEN1 (0.55) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL12789525 | 0.87 | HSPB1 (0.51) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL11282911 | 0.87 | MEN1 (0.54) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL10976077 | 0.87 | MEN1 (0.61) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL3888921 | 0.85 | TDP1 (0.60) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL11272985 | 0.85 | MEN1 (0.53) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL2424186 | 0.85 | TDP1 (0.61) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL11147168 | 0.85 | MEN1 (0.72) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL9768812 | 0.85 | MEN1 (0.72) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL7008104 | 0.84 | MEN1 (0.52) | TDP1MEN1KMT2ATTRPPOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1784390-A2 | SUBSTITUTED BENZOFUSED HETEROCYCLES | Amgen Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060199796-A1 | Substituted benzofused heterocycles | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
| WO-2006020959-A2 | SUBSTITUTED BENZOFUSED HETEROCYCLES | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199796-A1 | Substituted benzofused heterocycles | GPR119, SDHA, OGDH | TDP1 3707/4885MEN1 1909/4885KMT2A 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.